| Literature DB >> 8869807 |
M Ogawa1.
Abstract
Paclitaxel has shown a significant activity on esophageal cancer in a phase II trial. Irinotecan has established the single-agent efficacy on both gastric and colorectal cancer. Docetaxel has attained a significant activity on advanced gastric cancer and a 29% response rate on pancreatic cancer in a phase II trial. Tomudex has shown comparable activity to leucovorin and 5-fluorouracil in colorectal cancer.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8869807 DOI： 10.1097/00001622-199607000-00009
Source DB: PubMed Journal: Curr Opin Oncol ISSN： 1040-8746 Impact factor: 3.645